vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FIRSTSUN CAPITAL BANCORP (FSUN). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $110.0M, roughly 1.5× FIRSTSUN CAPITAL BANCORP). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
ESPR vs FSUN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $110.0M |
| Net Profit | — | $21.6M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 19.6% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | -8.4% |
| EPS (diluted) | $0.32 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $110.0M | ||
| Q4 25 | $168.4M | $110.2M | ||
| Q3 25 | $87.3M | $107.3M | ||
| Q2 25 | $82.4M | $105.6M | ||
| Q1 25 | $65.0M | $96.2M | ||
| Q4 24 | $69.1M | $98.7M | ||
| Q3 24 | $51.6M | $98.2M | ||
| Q2 24 | $73.8M | $96.2M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | — | $24.8M | ||
| Q3 25 | $-31.3M | $23.2M | ||
| Q2 25 | $-12.7M | $26.4M | ||
| Q1 25 | $-40.5M | $23.6M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | $-29.5M | $22.4M | ||
| Q2 24 | $-61.9M | $24.6M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 29.0% | ||
| Q3 25 | -11.4% | 26.4% | ||
| Q2 25 | 8.6% | 31.2% | ||
| Q1 25 | -34.0% | 30.9% | ||
| Q4 24 | -6.4% | 20.4% | ||
| Q3 24 | -31.0% | 29.1% | ||
| Q2 24 | 3.5% | 32.3% |
| Q1 26 | — | 19.6% | ||
| Q4 25 | — | 22.5% | ||
| Q3 25 | -35.9% | 21.6% | ||
| Q2 25 | -15.4% | 25.0% | ||
| Q1 25 | -62.2% | 24.5% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | -57.2% | 22.8% | ||
| Q2 24 | -83.9% | 25.5% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.32 | $0.89 | ||
| Q3 25 | $-0.16 | $0.82 | ||
| Q2 25 | $-0.06 | $0.93 | ||
| Q1 25 | $-0.21 | $0.83 | ||
| Q4 24 | $-0.14 | $0.57 | ||
| Q3 24 | $-0.15 | $0.79 | ||
| Q2 24 | $-0.33 | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $413.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.2B |
| Total Assets | $465.9M | $8.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $413.7M | ||
| Q4 25 | $167.9M | $652.6M | ||
| Q3 25 | $92.4M | $659.9M | ||
| Q2 25 | $86.1M | $785.1M | ||
| Q1 25 | $114.6M | $621.4M | ||
| Q4 24 | $144.8M | $615.9M | ||
| Q3 24 | $144.7M | $573.7M | ||
| Q2 24 | $189.3M | $535.8M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.1B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $1.1B | ||
| Q4 24 | $-388.7M | $1.0B | ||
| Q3 24 | $-370.2M | $1.0B | ||
| Q2 24 | $-344.2M | $996.6M |
| Q1 26 | — | $8.6B | ||
| Q4 25 | $465.9M | $8.5B | ||
| Q3 25 | $364.0M | $8.5B | ||
| Q2 25 | $347.1M | $8.4B | ||
| Q1 25 | $324.0M | $8.2B | ||
| Q4 24 | $343.8M | $8.1B | ||
| Q3 24 | $314.1M | $8.1B | ||
| Q2 24 | $352.3M | $8.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $111.5M | ||
| Q3 25 | $-4.3M | $49.4M | ||
| Q2 25 | $-31.4M | $15.0M | ||
| Q1 25 | $-22.6M | $26.4M | ||
| Q4 24 | $-35.0M | $101.1M | ||
| Q3 24 | $-35.3M | $48.1M | ||
| Q2 24 | $-7.2M | $20.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $104.0M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $24.3M | ||
| Q4 24 | — | $95.7M | ||
| Q3 24 | $-35.5M | $47.1M | ||
| Q2 24 | $-7.3M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 94.3% | ||
| Q3 25 | — | 44.4% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 97.0% | ||
| Q3 24 | -68.7% | 47.9% | ||
| Q2 24 | -9.9% | 20.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 6.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 5.5% | ||
| Q3 24 | 0.3% | 1.1% | ||
| Q2 24 | 0.1% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.49× | ||
| Q3 25 | — | 2.13× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 6.18× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | 0.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
